Research Use Only. Not for human or veterinary use. Not medical advice.

RC-LIV · Longevity Research

RC-LIV vial (catalog image)

RC-LIV

Longevity Research

Catalog code Research material Lyophilized format 20 mg vial
Presentation

Vial sizes for laboratory supply, not a protocol.

Pricing
Sign in
Researcher pricing for approved accounts
In stock
As listed on the public catalog, Nov 17, 2026
Add to cart
0 25 50 75
26 of 100

Popularity

Low

Public interest index

Research: Literature Activity 4/10 · Limited (PubMed volume)

Data as of Nov 17, 2026 · Sources: Wikipedia pageviews, Reddit, X public mentions.

Measures online attention only. It is not a measure of quality, purity, efficacy, or safety.

Publications per year

Unique PubMed records grouped by publication year — a volume index, not a quality rating.

PubMed counts

Last updated Nov 17, 2026. 19 unique records for (livagen). 2026 is a partial year. The named-compound corpus is small (19 unique records) and is narrowly sourced: a large share comes from a single short-peptide bioregulator research tradition. This page does not treat that corpus as broadly independently replicated. Source on PubMed

Key specifications

Catalog facts are taken from the live PEPTIDEA™ listing. Formula and molecular weight are from PubChem. Sequence is omitted here.

Catalog title
RC-LIV | Longevity Research
Research focus
Longevity Research
Also described as
Livagen · KEDA tetrapeptide (Lys-Glu-Asp-Ala)
Format
Lyophilized research peptide
Catalog status
In stock (public listing)
Presentations
20 mg vialCatalog sizes, not a protocol
Molecular formula
C18H31N5O9PubChem CID 87919683
Molecular weight
461.5PubChem average for CID 87919683
Receptor context
Described in the literature as a short synthetic tetrapeptide (Lys-Glu-Asp-Ala)PubChem and published identity literature; research context only
Sequence
Not reproduced hereSee primary literature / PubChem
Researcher access
Sign-in required to view pricing
PubMed records
19 uniqueQuery above, Nov 17, 2026

Catalog notes & use limitations

Research-catalog framing only. This section does not describe effects in people or study outcomes.

Catalog notes

Listed under Longevity Research

RC-LIV appears in the PEPTIDEA™ Longevity and Cellular Lifecycle Research collection with RC-EPI and RC-GLTA.

Narrowly sourced literature

Almost all of the named-compound records come from a single short-peptide bioregulator research tradition. This page states that limitation and does not treat the corpus as broadly replicated.

20 mg vial

The catalog presentation is a 20 mg vial. That is a presentation of the research material, not a protocol.

Use limitations

Research use only

Not for human or veterinary use. Not a drug, not a cosmetic, and not medical advice. Not presented here as a treatment or weight-management product.

No outcome or dosing information

This page does not list administration amounts, schedules, or clinical results. Catalog vial sizes are presentations of the research material, not a protocol.

Confirm details from primary sources

Formula and molecular weight are cited from PubChem when a single compound applies; otherwise see the catalog notes. Sequence is omitted. Read the original papers for laboratory context — results stay in the original publications.

Specifications

Laboratory-catalog and public-chemistry details. Items without a cited source are marked.

Catalog titleRC-LIV | Longevity Research
CategoryLongevity Research (Longevity and Cellular Lifecycle Research)
Associated namesLivagen; tetrapeptide Lys-Glu-Asp-Ala (KEDA)
FormatLyophilized research peptide
Public catalog statusIn stock (as of Nov 17, 2026)
Catalog presentations20 mg vial — sizes of the research material, not a use protocol
Molecular formulaC18H31N5O9 (PubChem CID 87919683, retrieved Nov 17, 2026)
Molecular weight461.5 (PubChem average for CID 87919683)
InChIKeyIKVDKWACACMDLR-BJDJZHNGSA-N (PubChem)
Receptor contextPublished papers from a narrowly sourced short-peptide bioregulator tradition describe Livagen as the tetrapeptide Lys-Glu-Asp-Ala (KEDA). That is an identity description, not a use claim, and it is not evidence of broad independent replication.
SequenceNot reproduced on this page. See primary literature and the PubChem record.
PricingVisible after researcher sign-in
CID 87919683 is cited for formula and mass.

Research literature

These are Peptidea-written summaries of selected publications, prepared so you can stay on peptidea.net. Each card describes what was studied — the research question, study type, and mechanism or setting. We do not restate results, endpoints, or protocols. Full papers remain with their publishers; a small PubMed source link is included only for citation.

Experimental, cell model — narrowly sourced

Khavinson et al.

Bulletin of Experimental Biology and Medicine · 2002
Livagen and chromatin in lymphocytes obtained from older donors

This paper examined Livagen in laboratory studies of chromatin in lymphocytes obtained from older donors. It is included as named-compound experimental literature. The donor description is a statement about the experimental material, not a use claim, and a large share of this literature comes from a single research tradition.

Chromatin-activation findings and any aging-application wording in the paper are not restated on this page.

Experimental, organotypic culture — narrowly sourced

Riadnova et al.

Advances in Gerontology · 2002
Livagen in an organotypic liver-culture model

This paper examined the peptide Livagen in an organotypic liver-culture model. It is a laboratory morphology study, not a clinical trial, and it belongs to the same narrowly sourced research tradition.

Morphological findings in the paper are not reproduced here.

Experimental, animal model — narrowly sourced

Timofeeva et al.

Advances in Gerontology · 2005
Livagen and digestive-enzyme activity in rats of different ages

This paper studied Livagen and digestive-enzyme activity in rats of different ages, including both gastrointestinal and other tissues. It is an animal laboratory study, not a study of this catalog vial in people.

Enzyme-activity measurements and any age-comparison findings in the paper are not restated on this page.

Experimental, biochemical — narrowly sourced

Kost et al.

Izvestiya Akademii Nauk, Seriya Biologicheskaya · 2003
Livagen and Epitalon in a study of enkephalin-degrading enzymes in human serum

This paper examined the peptides Livagen and Epitalon in a laboratory study of enkephalin-degrading enzymes in human serum. It is included as named-compound biochemical literature from the same research tradition, not as a clinical use study.

Enzyme findings in the paper are not reproduced here.

Original titles are omitted or neutralized when they use clinical-outcome wording. Counts and the optional source links use the query (livagen). Source on PubMed

Storage & handling

General laboratory-catalog guidance for layout purposes. Always follow the vial label and your institution’s written procedures.

  • Handle as a lyophilized research material intended for laboratory use only.
  • Store according to the conditions printed on the label and in any compound document provided to approved researchers.
  • Protect closed vials from moisture and unnecessary temperature swings.
  • If reconstitution is performed, use only the laboratory’s own written procedures. This page does not provide volumes, solvents, or working concentrations.
  • This material is not for human or veterinary use and is not medical advice.
No dosing, administration, or protocol instructions are included on this page.

Research Use Only. Not for human or veterinary use. Not medical advice. PEPTIDEA™ is a trademark of Grey Bug LLC.